EC approves Ranivisio, a biosimilar to Lucentis

29 August 2022

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) announced that the European Commission (EC) has granted a Marketing Authorization for Ranivisio/FYB201 (ranibizumab), a biosimilar of the ophthalmology treatment Lucentis across all five indications in adults for which Lucentis is authorized.

Teva entered into a strategic partnership with Bioeq in June 2021 for the exclusive commercialization of ranibizumab and intends to launch the product throughout Europe following its July ’2022 debut in the UK under the tradename Ongavia. Bioeq is the Switzerland-based of Dutch firm Polpharma Biologics and Germany’s Formycon.

Lucentis is marketed by Swiss pharma giants Roche (ROG: SIX) in the USA and Novartis (NOVN: VX) elsewhere.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK